Literature DB >> 3747613

Lymphadenectomy in the management of stage I malignant melanoma: a prospective randomized study.

F H Sim, W F Taylor, D J Pritchard, E H Soule.   

Abstract

A prospective randomized study was initiated at our institution in 1972 to determine the efficacy of routine elective lymphadenectomy in localized (stage I) melanoma. Included in the study were 171 patients, 62 of whom had no lymphadenectomy, 55 of whom had delayed lymphadenectomy, and 54 of whom had immediate lymphadenectomy. No significant difference was found among the three treatment groups with respect to survival or metastasis-free survival. Multifactorial analysis indicated that the level of invasion and the thickness of the lesion were the most important prognostic factors, followed by age (60 years or older), site (legs), and tumor type (nodular). A prognostic index based on these variables was highly predictive of metastasis or death. Even when this score was considered, no significant variation was noted among the three treatment groups. More subsequent complications of melanoma, however, occurred in the group with no lymphadenectomy--36 in this group but only 19 in each of the other treatment groups. This finding was not statistically significant but does indicate that a few additional problems may be associated with leaving regional nodes intact. Further studies are needed, and indeed are being conducted, to determine whether elective lymphadenectomy improves survival sufficiently to offset the costs and the complications associated with this approach.

Entities:  

Mesh:

Year:  1986        PMID: 3747613     DOI: 10.1016/s0025-6196(12)62768-2

Source DB:  PubMed          Journal:  Mayo Clin Proc        ISSN: 0025-6196            Impact factor:   7.616


  32 in total

1.  Combined endoscopic and open inguinal dissection for malignant melanoma.

Authors:  Claus Schneider; Jens P Brodersen; Hubert Scheuerlein; Carsten Tamme; Hans Lippert; Ferdinand Köckerling
Journal:  Langenbecks Arch Surg       Date:  2003-03-11       Impact factor: 3.445

2.  MSLT-I-response of clinical trial investigators.

Authors:  James C Yang; Richard M Sherry
Journal:  Nat Rev Clin Oncol       Date:  2014-10-14       Impact factor: 66.675

Review 3.  [Sentinel node biopsy. What are the facts?].

Authors:  M Möhrle; H Breuninger
Journal:  Hautarzt       Date:  2005-05       Impact factor: 0.751

4.  Sentinel node biopsy for early-stage melanoma: accuracy and morbidity in MSLT-1, an international multicenter trial.

Authors:  Patrick Twomey
Journal:  Ann Surg       Date:  2007-01       Impact factor: 12.969

5.  A retrospective analysis of the role of adjuvant radiotherapy in the treatment of cutaneous melanoma.

Authors:  Aaron Baker; Fabian Camacho; Genevieve Andrews; Heath Mackley
Journal:  Cancer Biol Ther       Date:  2016-09-16       Impact factor: 4.742

6.  Completing the Dissection in Melanoma: Increasing Decision Precision.

Authors:  Mark B Faries
Journal:  Ann Surg Oncol       Date:  2018-01-04       Impact factor: 5.344

7.  Management of regional lymph node basins in melanoma.

Authors:  Timothy P Love; Keith A Delman
Journal:  Ochsner J       Date:  2010

8.  Malignant melanoma of the head and neck: a brief review of pathophysiology, current staging, and management.

Authors:  Christian Hasney; R Brent Butcher; Ronald G Amedee
Journal:  Ochsner J       Date:  2008

Review 9.  The role of radiation therapy in the management of cutaneous melanoma.

Authors:  Charlene E Kan; David B Mansur
Journal:  Melanoma Manag       Date:  2016-02-24

Review 10.  Sentinel lymph node mapping and staging in endometrial cancer: A Society of Gynecologic Oncology literature review with consensus recommendations.

Authors:  Robert W Holloway; Nadeem R Abu-Rustum; Floor J Backes; John F Boggess; Walter H Gotlieb; W Jeffrey Lowery; Emma C Rossi; Edward J Tanner; Rebecca J Wolsky
Journal:  Gynecol Oncol       Date:  2017-05-28       Impact factor: 5.482

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.